Neutralizing peripheral circulating IL1β slows the progression of ALS in a lentivirus‐infected OPTN(E478G) mouse model

BACKGROUND: Amyotrophic lateral sclerosis (ALS) is irreversible and fatal within 3–5 years, with limited options for treatment. It is imperative to develop a symptom‐based treatment that may increase the survival of ALS patients and improve their quality of life. Inflammation status, especially elev...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Wen‐Bao, Wang, Xin, Pang, Zhi‐Lin, Duan, Ran, Hong, Chun‐Gu, Liu, Zheng‐Zhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Themed Section: Neurodegenerative Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986221/
https://www.ncbi.nlm.nih.gov/pubmed/36575589
http://dx.doi.org/10.1002/ame2.12297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986221/
https://www.ncbi.nlm.nih.gov/pubmed/36575589
http://dx.doi.org/10.1002/ame2.12297

Ejemplares similares